Company intelligence / Profile preview

NeoVentures Biotechnology Inc.

London, Ontario, Canadaneoaptamers.com ↗

Ownership: Private
Employees: ~11
Development stage: Preclinical

Overview

NeoVentures was the first company to commercialize an aptamer-based diagnostic device with their series of products for mycotoxin detection in 2008. They have developed aptamer-based detection systems with limits of detection in the femtomolar range in flow-through devices.

Therapeutic areas: CardiovascularNeurologyInfectious Diseases
Modalities: Aptamers
Industry: Biotech

Beyond the preview

Go deeper on NeoVentures Biotechnology Inc..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on NeoVentures Biotechnology Inc..

Explore the full profile